Physician profile
Douglas Jay Federman
NPI 1427043629
$2,248.79
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $196 · 2021: $417 · 2022: $301 · 2023: $90.97 · 2024: $57.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $893.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $266.54 | 2022-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $211.80 | 2019-2021 | |
| Pulmonx Corporation | $125.31 | 2021 | |
| Urovant Sciences INC | $124.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.96 | 2021 | |
| Novo Nordisk INC | $117.53 | 2019 | |
| Gilead Sciences, INC. | $102.05 | 2019-2021 | |
| Amarin Pharma, INC. | $83.19 | 2020-2021 | |
| Medtronic, INC. | $33.35 | 2024 | Minimed 780g |
| Lilly USA, LLC | $30.65 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.23 | 2019-2021 | |
| Abbott Laboratories | $24.30 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $21.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.50 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.16 | 2020 | |
| Mylan Specialty L.P. | $16.34 | 2019 | |
| Dynavax Technologies Corporation | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Federman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.